Furthermore, resminostat, a novel pan histone deacetylases inhibitor, has been shown to trigger mPTP-dependent apoptosis in hepatocellular carcinoma cells (HepG2, HepB3, SMMC-7721) and in patient-derived primary hepatocellular carcinoma cells after interaction which cyclophilin D and ANT-1 and followed by mitochondrial membrane depolarization, cytochrome c release and caspase activation [167]. Here, CYCS is linked to hepatocellular carcinoma.